TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
GHRS

GH Research PLC

Healthcare · Biotechnology

18.50$ -3.9% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns GH Research PLC (GHRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 47.2% of the shares are freely tradable; institutional investors hold 69.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 69.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 24.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 47.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 69Mio.

Largest Shareholders

Institutions

Institutions GHRS
Name Stake (%) Shares Change (%) Date
Lynx1 Capital Management, LP 19.32 13,263,288 +23.2 06/30/2026
Bvf Inc 12.60 8,650,158 +0.0 06/30/2026
RA Capital Management, LLC 11.13 7,636,813 -0.5 06/30/2026
FMR Inc 8.71 5,977,045 +16.4 06/30/2026
RTW INVESTMENTS, LLC 8.64 5,933,815 +0.0 06/30/2026
Deep Track Capital, LP 4.86 3,333,334 +0.0 06/30/2026
venBio Select Advisor LLC 2.62 1,800,000 +0.0 06/30/2026
Foresite Capital Management VI LLC 1.37 940,493 +198.1 06/30/2026
Jefferies Financial Group Inc 1.04 712,300 +0.0 06/30/2026

Funds

Funds GHRS
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 2.82 1,933,509 +2.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?